Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial.
Topic:
Lipids (Epidemiology and Prevention)
Speaker:
Professor M. Landray (Oxford, GB)
Event:
ESC Congress 2017
Congress Presentation
About the speaker
Professor Martin Landray
University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)
7
presentations
0
follower
Access the full session
About the event
ESC 365 is supported by
